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Candida glabrata is a commensal yeast in the human gut, genitourinary tract, or oral cavity; however, 
it can cause serious bloodstream infections (BSIs) that 
result in substantial illness and death (1). Unlike other 
common Candida species, C. glabrata exhibits intrinsi-
cally low susceptibility to azole drugs, especially flu-
conazole, and rapidly acquires antifungal resistance 
in response to azole or echinocandin exposure (1–3). 
Although the incidence of echinocandin- and multi-
drug-resistant (MDR) C. glabrata BSIs is low, flucon-
azole resistant (FR) C. glabrata BSI isolates have been 
increasingly reported worldwide, typically at rates of 
2.6%–10.6%, although these rates can reach 17% (4–6). 
Fluconazole resistance in C. glabrata is of particular 
concern because of the increased incidence of BSIs 
caused by this species in various locations world-
wide (1,4,5). Acquired azole resistance in C. glabrata 
is most commonly mediated by overexpression of the 
drug-efflux transporter genes CgCDR1, CgCDR2, and 
CgSNQ2 through a gain-of-function (GOF) mutation 
in the transcription factor pleiotropic drug-resistance 
(PDR1) (2,7,8), although other mechanisms might 
contribute (9–11).
PDR1 mutations in C. glabrata associated with 
azole resistance have been shown to cause hyper-
virulence in a mouse model of systemic candidiasis, 
suggesting the need for careful monitoring of FR C. 
glabrata BSI isolates and their PDR1 mutations (7,12). 
To date, little substantial research has been conduct-
ed on PDR1 mutation incidence among FR C. glabrata 
BSI isolates from multicenter surveillance cultures 
or on mortality rates of patients infected with these 
PDR1 mutants. This deficit might be attributable to 
Pdr1p amino acid substitutions (AAS) found in FR 
and fluconazole-susceptible dose-dependent (F-SDD) 
isolates (7,13,14), which can impede determination of 
whether specific Pdr1p AAS result in fluconazole re-
sistance. Therefore, the aim of this study was to inves-
tigate the clinical outcomes, molecular mechanisms, 
and genotypes associated with antifungal-resistant 
BSI isolates of C. glabrata collected during multicenter 
studies in South Korea during an 11-year period 
(2008–2018). We focused on the mortality rates of pa-
tients infected with FR C. glabrata BSI isolates harbor-
ing the Pdr1p mutation.
Materials and Methods
Microorganisms and Antifungal Susceptibility Testing
A total of 1,158 BSI isolates of C. glabrata were collect-
ed from 19 university hospitals in South Korea dur-
ing January 2008–December 2018 (Appendix Table 
1, https://wwwnc.cdc.gov/EID/article/27/3/20-
3482-App1.pdf). All isolates were collected from 
routine blood cultures by using methods that varied 
among laboratories; only the first isolate from each 
patient was included. The hospitals participating in 
this laboratory-based nationwide multicenter sur-
veillance system differed each year. All C. glabrata 
isolates were submitted to Chonnam National Uni-
versity Hospital (Gwangju, South Korea) for testing. 
Species identification was based on matrix-assisted 
laser desorption/ionization time-of-flight mass spec-
trometry (Biotyper; Bruker Daltonics, https://www.
bruker.com) with library version 4.0, or sequencing 
of the D1/D2 domains of the 26S rRNA gene, to dif-
ferentiate C. glabrata from cryptic species (C. nivarien-
sis and C. bracarensis) within the C. glabrata complex 
(15). In vitro testing of susceptibility to fluconazole, 
micafungin, caspofungin, voriconazole, and ampho-
tericin B was performed for all isolates according 
to the Clinical and Laboratory Standards Institute 
broth microdilution method (16). MICs were deter-
mined after 24 hours of incubation. Two reference 
strains, Candida parapsilosis ATCC 22019 and Candida 
krusei ATCC 6258, were included in each antifungal 
susceptibility test as quality-control isolates. The 
MIC interpretive criteria included species-specific 
Clinical and Laboratory Standards Institute clinical 
breakpoints for fluconazole, micafungin, and caspo-
fungin (17), as well as epidemiologic cutoff values 
(ECVs) for voriconazole and amphotericin B (18). 
Echinocandin resistance was confirmed through 
DNA sequence analysis of FKS genes to identify re-
sistance hot-spot mutations in FKS1 and FKS2 (19). 
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We investigated the clinical outcomes and molecular 
mechanisms of fluconazole-resistant (FR) Candida gla-
brata bloodstream infections. Among 1,158 isolates col-
lected during multicenter studies in South Korea during 
2008–2018, 5.7% were FR. For 64 patients with FR 
bloodstream infection isolates, the 30-day mortality rate 
was 60.9% and the 90-day mortality rate 78.2%; these 
rates were significantly higher than in patients with flucon-
azole-susceptible dose-dependent isolates (30-day mor-
tality rate 36.4%, 90-day mortality rate 43.8%; p<0.05). 
For patients with FR isolates, appropriate antifungal ther-
apy was the only independent protective factor associ-
ated with 30-day (hazard ratio 0.304) and 90-day (hazard 
ratio 0.310) mortality. Sequencing of pleiotropic drug-re-
sistance transcription factor revealed that 1–2 additional 
Pdr1p amino acid substitutions (except genotype-specific 
Pdr1p amino acid substitutions) occurred in 98.5% of 
FR isolates but in only 0.9% of fluconazole-susceptible 
dose-dependent isolates. These results highlight the high 
mortality rate of patients infected with FR C. glabrata BSI 
isolates harboring Pdr1p mutations.
 Fluconazole-Resistant C. glabrata, South Korea
Multidrug resistance was defined as resistance to 
both fluconazole and echinocandins (2).
Clinical Characteristics
Candidemia was defined as the isolation of Candida 
from >1 blood culture (20), and cases with invasive 
candidiasis without candidemia or colonization were 
excluded. All demographic characteristics and clinical 
conditions potentially related to candidemia mortal-
ity rates at the time of candidemia onset were investi-
gated (21–23). Previous use of antifungal agents was 
defined as administration within 3 months before the 
onset of candidemia. A lack of antifungal therapy was 
defined as no antifungal therapy or treatment with 
antifungals for <3 days; appropriate antifungal ther-
apy was defined as the administration of >1 in vitro–
active antifungal (according to the susceptibility pat-
tern of the isolate) for >72 hours (23,24). Therapeutic 
failure was defined as either persistence of Candida in 
the bloodstream despite >72 hours of antifungal ther-
apy or development of breakthrough fungemia dur-
ing treatment with the indicated antifungal agents for 
>72 hours (23,24). All-cause mortality rates were as-
sessed at 30 and 90 days after the first positive blood 
culture result. Mortality rates also were analyzed for 
patients with candidemia who were infected with 
297 SDD isolates of C. glabrata as controls. This study 
was approved by the Institutional Review Board of 
Chonnam National University Hospital (approval no. 
CNUH-2020-117).
Multilocus Sequence Typing and Molecular Mechanisms
Multilocus sequence typing (MLST) and PDR1 se-
quencing were performed for all antifungal-resis-
tant isolates of C. glabrata and for 212 F-SDD con-
trol isolates by using methods described previously 
(14,21,25). PDR1 sequences of each isolate were com-
pared and analyzed on the basis of the reference 
PDR1 sequence of C. glabrata (GenBank accession 
no. FJ550269) (14). The FKS1 and FKS2 sequences of 
79 isolates that exhibited full or intermediate resis-
tance to micafungin (MIC >0.12 mg/L) or caspofun-
gin (MIC >0.25 mg/L) were compared with those of 
C. glabrata (GenBank reference sequence nos. FKS1 
XM_446406 and FKS2 XM_448401) (14). The expres-
sion levels of CgCDR1, CgCDR2, and CgSNQ2 were 
evaluated for 30 FR isolates of C. glabrata harbor-
ing FR-specific Pdr AAS and for 65 F-SDD control 
isolates without FR-specific Pdr AAS, as described 
previously (26,27). The cycle threshold (Ct) of each 
gene was normalized to that of URA3 to determine 
the ΔCt value. For all isolates, relative gene expres-
sion (ΔΔCT) was reported as fold change calculated 
as the mean normalized expression level relative to 
that of C. glabrata ATCC 90030 (fluconazole MIC 8 
mg/L, set as 1.0).
Statistical Analysis
Quantitative variables are expressed as means with 
standard deviations, whereas categorical variables 
are expressed as counts and percentages. Categori-
cal variables were compared by using the χ2 test or 
Fisher exact test, Student t–test or the Mann–Whit-
ney U test to compare quantitative variables, as ap-
propriate. Cox proportional hazards models were 
used to evaluate potential risk factors for 30- and 
90-day mortality rates by calculating the hazard ra-
tio (HR). The Kaplan–Meier and log–rank (Mantel–
Cox) tests were used to calculate the 30- and 90-day 
survival probabilities in subgroup analyses. All data 
were analyzed by using SPSS Statistics 26.0 (IBM, 
https://www.ibm.com). Statistical significance was 
determined at a level of p<0.05.
Results
Incidence of Antifungal Resistance
The annual proportion of C. glabrata BSI isolates 
among all Candida BSI isolates increased from 11.7% 
to 23.9% (mean 18.6%) during the study period (Table 
1). The rate of fluconazole resistance (MIC >64 mg/L) 
increased from 0% (0/68 isolates) to 8.3% (14/168 
isolates) during the study period. Among the 1,158 
BSI isolates of C. glabrata, 66 (5.7%) were resistant to 
fluconazole, 16 (1.4%) were resistant to echinocandin, 
and 6 (0.5%) were resistant to multiple drugs. Of the 
16 echinocandin-resistant isolates, 6 (37.5%) were 
also resistant to fluconazole; thus, these isolates were 
MDR. Isolates of echinocandin-resistant and MDR C. 
glabrata were initially found in 2013 and then annu-
ally from 2016 to 2018. Resistance to amphotericin B 
(MIC >2 mg/L) was not detected in any isolate, but 79 
(6.8%) isolates had voriconazole MICs that exceeded 
the ECV (0.25 mg/L). All 64 FR isolates were associ-
ated with a voriconazole MIC >0.5 mg/L.
Mortality Rate of FR Candida glabrata BSIs
The mortality rate for 64 patients with FR C. glabrata 
BSI isolates was 60.9% at 30 days (Appendix Table 
2). Univariate Cox regression analyses revealed 
that a high Charlson comorbidity index (p = 0.051), 
liver disease (p = 0.015), intensive-care unit admis-
sion (p = 0.071), severe sepsis (p = 0.039), lack of 
antifungal therapy (p<0.001), azole monotherapy 
(p = 0.005), any combination antifungal therapy 
(p = 0.014), and appropriate antifungal therapy 
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(p = 0.001) were associated with the 30-day mortality 
rate. The 30-day mortality rates were 88.9% (8/9) 
in patients with azole monotherapy, 69.2% (9/13) 
in patients with echinocandin monotherapy, 70% 
(7/10) in patients with amphotericin B monother-
apy, 36.4% (8/22) in patients with combination an-
tifungal therapy, 90% (18/20) in patients with in-
adequate antifungal therapy, and 47.7% (21/44) in 
patients with appropriate antifungal therapy. Pa-
tients treated with azole monotherapy or inadequate 
antifungal therapy showed significantly higher 30-
day mortality rates than those receiving combina-
tion therapy or appropriate antifungal therapy (all 
p<0.05). In multivariate Cox regression analysis, no 
independent risk factors for 30-day mortality were 
identified, but appropriate antifungal therapy (HR 
0.304 [95% CI 0.134–0.689]; p = 0.004) was indepen-
dently protective with respect to 30-day mortality. 
The mortality rate for 64 patients with FR C. glabrata 
BSI isolates was 78.2% at 90 days; appropriate anti-
fungal therapy (HR 0.31 [95% CI 0.138–0.695]; p = 
0.004) was the only protective factor with respect to 
90-day mortality (Appendix Table 3). Kaplan–Meier 
survival analysis showed that the mortality dynam-
ics of the FR group (64 patients) decreased during 
the study period, whereas the F-SDD group (297 
patients) exhibited a plateau period of decreasing 
cumulative survival from 30 to 90 days, which was 
similar in each of the 4 years of the study period 
(Figure). The median survival of patients with FR 
C. glabrata BSI was significantly shorter than that of 
patients with F-SDD C. glabrata (17 days for FR vs. 90 
days for F-SDD; p<0.001 by log-rank test).
MLST Genotypes and AAS in Pdr1p
MLST revealed that 56.1% (37/66) of FR, 56.3% (9/16) 
of echinocandin-resistant, and 100% (6/6) of MDR 
isolates belonged to sequence type (ST) 7. Table 2 lists 
the sequencing results for PDR1 and the MLST geno-
types for the 66 FR isolates of C. glabrata, as well as 
212 control F-SDD isolates. In total, 68 types of AAS 
in Pdr1p were found in the 278 isolates of C. glabrata 
tested. When Pdr1p polymorphisms were compared 
between >2 isolates in the same ST (257 isolates in 11 
STs), excluding 21 STs that were unique to a single 
isolate, all 50 ST3 isolates harbored the same 3 Pdr1p 
AAS (P76S, P143T, and D243N), all 8 ST55 isolates 
harbored E259G, and all 4 ST59 isolates harbored 
T745A, irrespective of FR. However, these 5 Pdr AAS 
were not found in any ST7 isolates or any isolates of 
the other 7 ST groups, each of which contained >2 
isolates. Excluding 5 Pdr1 AAS (P76S, P143T, D243N, 
E259G, and T745A), 1 additional Pdr1p AAS was 
found in each of 2 F-SDD isolates (0.9%, n = 212); 1 (59 
FR isolates) or 2 (6 FR isolates) additional Pdr1p AAS 
was found in 65/66 (98.5%) FR isolates.
AAS in Pdr1p Shown in Only FR isolates
Each of the 49 Pdr1p AAS was found alone in 59 FR 
isolates of C. glabrata and their MLST genotypes (Ta-
ble 3). In 38 (64.4%) isolates, AAS were found in 3 do-
mains of Pdr1p, the inhibition (33.9%), fungal-specific 
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Table 1. Incidence of antifungal resistance in Candida glabrata BSI isolates, based on cultures collected during a multicenter 





% C. glabrata of all 
Candida BSI isolates 
No. BSI isolates of 
C. glabrata tested 







2008 13 11.7 68 0 0 0 
2009 8 16.0 67 4 (6.0) 0 0 
2010 8 16.8 60 4 (6.7) 0 0 
2011 10 16.0 85 4 (4.7) 0 0 
2012 11 17.0 108 3 (2.8) 0 0 
2013 7 16.9 73 4 (5.5) 1 (1.4) 1 (1.4) 
2014 7 22.1 123 11 (8.9) 0 0 
2015 10 17.2 110 5 (4.5) 3 (2.7) 0 
2016 10 21.2 123 4 (3.3) 4 (3.3) 2 (1.6) 
2017 13 21.6 173 13 (7.5) 4 (2.3) 1 (0.6) 
2018 13 23.9 168 14 (8.3) 4 (2.4) 2 (1.2) 
Total 19 18.6 1158 66 (5.7) 16 (1.4) 6 (0.5) 
*BSI, bloodstream infection. 
†Hospitals participating in this laboratory-based nationwide multicenter surveillance system differed each year. 
‡Antifungal susceptibility was determined by using the Clinical and Laboratory Standards Institute M27–4ED broth microdilution method (16). Interpretive 
categories of resistance were determined by using Clinical and Laboratory Standards Institute document M60-ED (17). We deposited 76 antifungal-
resistant isolates of C. glabrata in the Korea Collection for Type Culture (KCTC; Jeongeup-si, Korea), including those showing resistance to fluconazole 
alone (60 isolates, KCTC nos. 37113–37172), echinocandin alone (10 isolates, KCTC nos. 37176–37185), and both fluconazole and echinocandin (6 
multidrug-resistant isolates, KCTC nos. 37110–37112, 37173–37175). All 76 isolates were identified as C. glabrata by sequence analysis using the D1/D2 
domain (GenBank accession nos. MW349716–90 and MW351777). 
§Echinocandin resistance was confirmed by the identification of resistance hot-spot mutations in FKS1 and FKS2 in isolates that exhibited full or 
intermediate resistance to micafungin (MIC >0.12 mg/L) or caspofungin MIC (>0.25 mg/L). 
¶Multidrug resistance was defined as resistance to both fluconazole and echinocandins. 
 
 Fluconazole-Resistant C. glabrata, South Korea
transcription factor (11.9%), and activation (18.6%) 
domains; AAS were outside the main domains in 21 
(35.6%) isolates. Of 49 Pdr1p AAS, 16 were described 
previously for FR isolates, whereas 33 (67.3%) were 
newly found in this study. Of these potentially nov-
el Pdr1p AAS, 5 (P327L, G346S, H576Y, T607A, and 
G788W) were shared by 2 isolates with the same gen-
otype. Among these, 2 AAS (G346S [ST2] and H576Y 
[ST7]), were shared by 2 isolates from the same hos-
pital in the same year. Quantitative reverse transcrip-
tion PCR revealed that 30 FR isolates harboring the 
Pdr mutation exhibited significantly higher mean 
expression levels of CgCDR1, CgCDR2, and CgSNQ2 
than 65 control F-SDD isolates (FR vs. F-SDD; 11.5- vs. 
1.5-fold for CgCDR1, p<0.0001; 43.4- vs. 27.0-fold for 
CgCDR2, p = 0.0408; and 4.9- vs. 3.5-fold for CgSNQ2, 
p = 0.0174) (Appendix Figure).
Discussion
After C. albicans, C. glabrata is the most common Can-
dida species isolated from BSI in North America and 
in countries of central and northern Europe (1,4). C. 
glabrata was the fourth most common BSI-causing 
Candida species in many countries in Asia besides 
South Korea (6,28,29); however, increasing rates of C. 
glabrata with FR have been reported in China (30), and 
this strain is now the second most common species 
in South Korea (31). In this study, the FR rate of BSI 
isolates of C. glabrata were found to have increased 
from 0% (0/68) in 2008 to 8.3% (14/168) in 2018. No 
C. glabrata isolate collected during 2008–2012 was 
resistant to echinocandins, whereas 2%–3% were re-
sistant to echinocandins during 2015–2018. The emer-
gence of echinocandin-resistant BSI isolates of C. gla-
brata in South Korea might reflect the increased use 
of echinocandin antifungals as the initial option for 
candidemia after insurance coverage for echinocan-
dins began in 2014 (32). Of 16 echinocandin-resistant 
isolates, 6 (37.5%) were also resistant to fluconazole, 
indicating multidrug resistance. Overall, our 11-year 
nationwide surveillance revealed an increasing in-
cidence of C. glabrata causing BSI and an increasing 
propensity for development of antifungal resistance 
in South Korea, consistent with surveillance data 
from other countries (1,2,4,5,30).
Data are scarce regarding the mortality rates for 
patients with candidemia who are infected with FR 
C. glabrata BSI isolates. The 30-day mortality rates 
in patients infected with C. glabrata BSI isolates are 
21.3%–48.6% (16,33–37) but can reach 50%–60% 
among patients in intensive care units (38,39). How-
ever, few FR C. glabrata isolates were included in 
previous studies. We found that FR BSI isolates of 
C. glabrata in South Korea were associated with sig-
nificantly higher 30-day (60.9%) and 90-day (78.2%) 
mortality rates, compared to BSIs caused by F-SDD 
strains (30-day mortality rate 36.4%, 90-day mortal-
ity rate 43.8%). The mortality dynamics of FR isolates 
indicated a rapid rise in cumulative mortality from 
7 to 90 days after BSI onset. This mortality dynamic 
was distinct from that of patients with F-SDD BSIs, 
who exhibited a steady curve after 60 days, consistent 
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Figure. Kaplan–Meier and log-rank (Mantel–Cox) pairwise analyses of survival of patients with Candida glabrata candidemia, based 
on patient data and cultures collected during a multicenter surveillance study, South Korea, 2008–2018. A) Cumulative survival curves 
of 64 patients infected with fluconazole-resistant (FR) bloodstream infection (BSI) isolates. The cumulative mortality rates of 64 
patients infected with FR C. glabrata BSIs increased over time (day 7 [29.7%], day 30 [60.9%], day 60 [68.8%], and day 90 [78.1%]). 
B) Cumulative survival curves of patients infected with fluconazole-susceptible dose-dependent (F-SDD) BSI isolates (297 patients 
total) in 2009 (75 patients in 6 hospitals), 2014 (97 patients in 7 hospitals), 2017 (75 patients in 9 hospitals), and 2018 (50 patients in 8 
hospitals). The 30-day mortality rate of the F-SDD group was 34.7% in 2010, 39.2% in 2014, 37.3% in 2017, and 32.0% in 2018. The 
cumulative mortality rates of 297 patients infected with F-SDD BSI isolates of C. glabrata were found to be 18.5% at day 7 (p = 0.084), 
36.4% at day 30 (p = 0.001), 41.8% at day 60 (p<0.001), and 43.8% at day 90 (p<0.001).
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with previous reports of C. glabrata BSIs (34,40). The 
median survival of patients with FR C. glabrata BSIs 
(17 days) was also significantly shorter than that of 
patients with F-SDD C. glabrata BSIs (90 days). These 
findings are consistent with the results in a recent re-
port regarding C. glabrata BSIs in South Korea, which 
showed that a high fluconazole MIC was associated 
with a poor outcome, although only 5 isolates in that 
study were FR (37).
In this study, MLST revealed that 56.1% of FR 
and 56.3% of echinocandin-resistant BSI isolates 
belonged to ST7, which accords with ST7 being the 
most common MLST genotype (47.8%) in South Ko-
rea (21). We found that 100% (6/6) of MDR isolates 
belonged to ST7, which harbored the V239L muta-
tion in the mismatch repair gene (MSH2) associated 
with hypermutability (21,25). Given that the utility 
of MSH2 gene mutations as antifungal-resistance 
markers remains controversial (41,42), further sur-
veillance studies are needed. To date, few studies 
have been conducted on MLST genotype–specific 
differences in Pdr1p polymorphism among C. gla-
brata BSI isolates. We found that all 50 isolates of 
ST3 harbored the same Pdr1p AAS (P76S/P143T/
D243N), all 7 isolates of ST55 harbored E259G, 
and all 4 isolates of ST59 harbored T745A, suggest-
ing the presence of MLST genotype–specific Pdr1p 
AAS. P76S/P143T/D243N in Pdr1p was found to be 
common in China, Iran, and Australia (13,14,43,44), 
which accords with the high prevalence of ST3 in 
the study collections. Thus, the results of this study 
suggest that 5 Pdr1p AAS are MLST genotype–spe-
cific; because these AAS were found in both FR and 
F-SDD isolates, we confirmed that they cannot be re-
sponsible for azole resistance.
A single-point mutation in PDR1 can contribute 
to azole resistance in C. glabrata (7,8). Our results 
show that, in FR isolates, AAS are scattered through-
out the entire protein without distinct hotspots, as re-
ported previously (7,13,41,45). Therefore, determin-
ing whether a certain Pdr1p AAS is a GOF mutation is 
difficult without data from gene editing experiments 
for all variable regions. A previous study identified 
57 FR-specific AAS by comparing azole-susceptible 
and azole-resistant matched isolates recovered from 
different clinical specimens (7). Furthermore, 91% 
(74/81) of FR isolates from BSIs or vaginal infections 
contained a Pdr1 mutation, compared with 5.6% 
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Table 2. Pdr1 AAS in 66 FR isolates and 212 F-SDD BSI isolates of Candida glabrata and their MLST genotypes, based on cultures 











No. isolates with 5 Pdr1p AAS found in 
both FR and F-SDD isolates 
 
No. isolates with additional Pdr1p 
AAS except for 5 Pdr1p AAS 
P76S P143T D243N E259G T745A 1 2 Total 
ST7 FR 37 6† 
     
34 3 37  
F-SDD 98 3 




ST3 FR 7 0 7 7 7 
   
6 1 7  
F-SDD 43 1 43 43 43 




ST26 FR 7 0 




F-SDD 10 1 




ST22 FR 1 0 




F-SDD 16 1 




ST10 FR 2 0 




F-SDD 9 0 




ST55 FR 2 0 






F-SDD 6 1 






ST2 FR 2 0 




F-SDD 3 0 




ST6 FR 1 0 




F-SDD 5 2 




ST59 FR 1 0 






F-SDD 3 1 






ST1 FR 2 0 




ST12 F-SDD 2 0 




Other STs‡ FR 4 0 
   
1 
  
2 2 4 
F-SDD 17 0 2 2 2 




Total, no. (%) FR 66 6 7 7 7 3 1 
 
59 6§ 65 (98.5) 





*AAS, amino acid substitution; BSI, bloodstream infection; FR, fluconazole-resistant; F-SDD, fluconazole-susceptible dose-dependent; MLST, multilocus 
sequence typing; ST, sequence type. 
†All 6 isolates showed multidrug resistance, defined as resistance to both fluconazole and echinocandins. 
‡Includes 21 STs that were each unique to a single isolate. 
§Each of 6 FR isolates harbored 2 additional Pdr1 AAS (E340G/D919Y [ST7], Y556C/F580I [ST7], N132S/G1099S [ST7], F832L/L833V [ST3], 
G189V/E340G [other ST], and L366P/E555D [other ST]). 





 Fluconazole-Resistant C. glabrata, South Korea
(1/18) of F-SDD isolates (25). In our study, we found 
that 98.5% (65/66) of FR BSI isolates and 0.9% (2/212) 
of F-SDD BSI isolates harbored an additional 1 or 2 
Pdr1p AAS after exclusion of 5 genotype-specific 
AAS (P76S, P143T D243N, E259G, and T745A). After 
exclusion of 6 additional FR isolates that harbored 2 
Pdr1p AAS (because determining which of the 2 AAS 
was critical for fluconazole resistance was difficult to 
determine), we found 49 Pdr1p AAS that were pres-
ent alone in 59 FR isolates, strongly suggesting that 
these AAS were FR-specific. Of the 49 Pdr1p AAS, 
16 have been described for FR isolates (7,13,14,25,43–
46). In this study, FR isolates exhibited higher mean 
CgCDR1, CgCDR2, or CgSNQ2 expression levels, 
compared with F-SDD isolates; all FR C. glabrata iso-
lates were also resistant to voriconazole (MIC >0.5 
mg/L), implying that fluconazole and voriconazole 
resistance are governed by the same mechanism (i.e., 
a GOF mutation in the transcription factor for Pdr1p) 
(7,8). Overall, our findings demonstrate that most FR 
BSI isolates of C. glabrata in South Korea harbor FR-
specific Pdr1p AAS.
The cause of the high mortality rate associat-
ed with FR C. glabrata BSIs remains unclear. In this 
study, we focused on FR-specific Pdr1p AAS. PDR1 
mutations are associated with increased virulence 
of C. glabrata, expression of adhesins, and adherence 
to host epithelial cells (7,12,47,48). The fungal loads 
in the kidney, spleen, and liver were higher in mice 
infected with the FR Pdr1 mutant of C. glabrata than 
in mice infected with F-SDD isolates (12). C. glabrata 
might persist in the body by replicating inside phago-
cytes, eventually leading to cell lysis, rather than by 
active escape (the method used by C. albicans) (47,49). 
This process might partly explain the elevated cumu-
lative mortality rate for patients with Pdr1 mutants. 
Appropriate antifungal therapy was the only inde-
pendently associated protective factor, with respect 
to 30- and 90-day mortality rates, in patients infected 
with FR C. glabrata isolates. In patients who received 
inadequate antifungal therapy and azole monothera-
py, the 30-day mortality rates were 90% (antifungal 
therapy) and 88.9% (azole monotherapy), which were 
significantly higher than those of the patients receiv-
ing combination therapy (36.4%) or appropriate anti-
fungal therapy (47.7%). Previous antifungal exposure 
was not an independent risk factor for death among 
patients with FR isolates, although it was identified 
in 62.5% (40/64) of patients. Given that previous 
antifungal exposure is a risk factor for antifungal-
resistant Candida BSI (50), further studies including F-
SDD C. glabrata BSIs might elucidate the relationship 
between previous antifungal exposure and death. 
Taken together, these findings suggest that the high 
mortality rate associated with FR C. glabrata BSIs can 
be explained by the combination of FR and the viru-
lence of Pdr1 mutants.
The first limitation of our study is that a Candida 
species might develop resistance within a patient dur-
ing antifungal therapy; such resistance can be iden-
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Table 3. Pdr1 AAS in 59 FR isolates of Candida glabrata BSI isolates and their MLST genotypes, based on cultures collected during a 





Pdr1 AAS (no. isolates)† 
Inhibition domain 
Fungal-specific 
transcription factor domain Activation domain Other regions 
ST7 34 P327L (2), G334V (1), 
E340G (1), E340K (1), 
G346S (1), L347F (1), 
L375P (1), R376Q (1), 
S391L (1) 
H576Y (2), G583C (1) P927S (1), G943S (1), 
S947L (1), D954N (1), 
G1088E (1), Y1106N (1) 
S236N (1), P258S (1), 
P258L (1), V260A (1),L280S 
(1), Y556C (1), E714D (1), 
T752I (1), N768D (1), R772K 
(1), K776E (1), G788W (2), 
L825P (1), T885A (1) 
ST26 6 K365E (1), R376Q (1), 
F377I (1), E388Q (1) 
 
N1091D (1) S316I (1) 





ST2 2 G346S (2) 
   
ST10 2 S337F (1), I392M (1) 
   
ST55 2 
   









ST59 1 E369K (1) 








59 20 (33.9) 7 (11.9) 11 (18.6) 21 (35.6) 
No. (%) 
Pdr1 AAS 
49 15 (30.6) 5 (10.2) 10 (20.4) 19 (38.8) 
*AAS, amino acid substitutions; BSI, bloodstream infection; FR, fluconazole-resistant; MLST, multilocus sequence typing; ST, sequence type. 
†Previously reported Pdr1 AAS are shown in bold. 
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tified through serial isolates, but we tested only the 
first isolate from each patient during 2016–2018. Sec-
ond, our results did not show that FR, PDR1 mutants, 
or previous antifungal exposure were independent 
risk factors for death in patients with C. glabrata BSIs. 
A total of 1,158 nonduplicate BSI isolates of C. glabrata 
from 19 university hospitals in South Korea were ob-
tained during the 11-year study period, and the hospi-
tals participating differed each year; therefore, we could 
not select an appropriate control group of F-SDD iso-
lates. These limitations were partly overcome in a recent 
study involving 197 adult patients with C. glabrata BSI 
during January 2010–February 2016 at 7 university hos-
pitals in South Korea. In that study, FR was shown to be 
associated with the 30-day mortality rate in a multivari-
ate analysis (37). Third, only limited numbers of patients 
infected with F-SDD BSI isolates of C. glabrata were in-
cluded in our mortality analysis. Nevertheless, we in-
cluded a total of 297 patients infected with F-SDD BSI 
isolates of C. glabrata, which included all patients with 
C. glabrata from the participating hospitals in 2010, 2014, 
2017, and 2018. The 30-day mortality rates of patients 
infected with F-SDD C. glabrata isolates were similar 
among those 4 years (32.0%–39.2%), despite differences 
in participating hospitals and collection periods; the 30-
day mortality rate was similar to those reported in pre-
vious studies (21,33–37). 
In conclusion, we demonstrated that nearly all 
FR BSI isolates of C. glabrata in South Korea harbored 
FR-specific Pdr1p mutations by excluding MLST 
genotype–specific Pdr1p AASs and that the isolates 
were associated with higher 30-day (60.9%) and 90-
day (78.2%) mortality rates. These results suggest 
that Pdr1 mutants are associated with a risk for death 
in such patients. In addition, appropriate antifungal 
therapy was the only independent protective factor 
against death in patients with FR isolates. Because of 
the increasing prevalence of FR BSI isolates of C. gla-
brata worldwide, improved detection and appropri-
ate antifungal treatments are critical.
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